< Back to search
Filter
1

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

for
Advanced Solid Tumors
Location: Portland OR
Sponsor: Providence Health & Services

Sex: All

Age: 18+

Code: NCT06719362

Phase1, Recruiting

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

for
HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC),
Location: Boston MA, New Haven CT, Fairfax VA, Morgantown WV,
Sponsor: NiKang Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07029399

Phase1, Recruiting

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

for
Mesothelioma, Non Small Cell Lung Cancer,
Location: Brookline MA, Port Jefferson Station NY, Mineola NY,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT05245500

Phase1, Recruiting

A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

for
Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer,
Location: Boston MA, New York NY, Houston TX, San Antonio TX,
Sponsor: Monopteros Therapeutics Inc.

Sex: All

Age: 18+

Code: NCT04859777

Phase1, Recruiting

Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors

for
Metastatic Solid Tumor, Locally Advanced Solid Tumor
Location: Salt Lake City UT
Sponsor: University of Utah

Sex: All

Age: 18+

Code: NCT06358677

Phase2, Recruiting

Interested in new advanced solid tumor trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors

for
Advanced Solid Tumors
Location: Houston TX
Sponsor: Purinomia Biotech, Inc.

Sex: All

Age: 18+

Code: NCT05234853

Phase1, Recruiting

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

for
Advanced Solid Tumors That Are MTAP Deficient
Location: Providence RI, New Haven CT, Baltimore MD, Fairfax VA,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06130553

Phase1, Phase2, Recruiting

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

for
Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer,
Location: New York NY, Huntersville NC
Sponsor: GI Innovation, Inc.

Sex: All

Age: 18+

Code: NCT04977453

Phase1, Phase2, Recruiting

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

for
Advanced Solid Tumor, Homologous Recombination Deficiency,
Location: Houston TX
Sponsor: Eisbach Bio GmbH

Sex: All

Age: 18+

Code: NCT06525298

Phase1, Phase2, Recruiting

Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

for
Tumor, Solid, Tumor, Advanced Solid Tumor
Location: San Antonio TX, West Valley City UT
Sponsor: Aadi Bioscience, Inc.

Sex: All

Age: 18+

Code: NCT05661461

Phase1, Recruiting

A Study in Patients With Advanced Cancers

for
Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
Location: Fairfax VA, Houston TX, Austin TX
Sponsor: BiOneCure Therapeutics Inc.

Sex: All

Age: 18+

Code: NCT05320588

Phase1, Phase2, Recruiting

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

for
Advanced Solid Tumors
Location: Boston MA, Philadelphia PA, Fairfax VA, Houston TX,
Sponsor: Tagworks Pharmaceuticals BV

Sex: All

Age: 18+

Code: NCT06959706

Phase1, Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

for
Advanced Solid Tumor, Advanced Breast Cancer,
Location: Durham NC, Columbus OH, Nashville TN, Denver CO,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06120283

Phase1, Recruiting

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

for
Advanced Solid Tumors
Location: Lake Success NY, Hackensack NJ, Charlotte NC,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT06697197

Phase1, Phase2, Recruiting

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

for
Advanced Solid Tumor
Location: New Haven CT, Madison WI, Houston TX, Seattle WA,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06625593

Phase1, Recruiting

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

for
Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
Location: New York NY, Fairfax VA, Cleveland OH, Lexington KY,
Sponsor: TORL Biotherapeutics, LLC

Sex: All

Age: 18+

Code: NCT05103683

Phase1, Recruiting

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

for
Metastatic Hepatocellular Carcinoma, Solid Tumors,
Location: Boston MA, New York NY, Baltimore MD, Toronto,
Sponsor: Tyra Biosciences, Inc

Sex: All

Age: 18+

Code: NCT06915753

Phase1, Recruiting

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

for
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Location: Boston MA, New York NY, Baltimore MD,
Sponsor: Nuvalent Inc.

Sex: All

Age: 18+

Code: NCT06521554

Phase1, Recruiting

Study of AVZO-021 in Patients With Advanced Solid Tumors

for
Advanced Solid Tumor, HR+/HER2- Breast Cancer,
Location: New Haven CT, Mineola NY, New York NY, Philadelphia PA,
Sponsor: Avenzo Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05867251

Phase1, Phase2, Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

for
Advanced Solid Tumors, Colorectal Cancer
Location: New Brunswick NJ, Toronto, Atlanta GA, Ann Arbor MI,
Sponsor: Vividion Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06004245

Phase1, Recruiting